Annual data report on surgical treatment of esophageal cancer in Shanghai Chest Hospital in 2015_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

GUO Xufeng , JIANG Haoyao , HUA Rong , LI Bin , ZHANG Xiaobin , SUN Yifeng ,  LI Zhigang

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P.R.China;

Corresponding author：

LI Zhigang, Email: dr_lizhigang@163.com

Keywords：

Esophageal cancer; esophagectomy; multidisciplinary treatment

DOI：

10.7507/1007-4848.202001006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To give an annual data report of surgical treatment of esophageal cancer in Shanghai Chest Hospital to provide reference for treatment and research on esophageal cancer.Methods The clinical data of 414 patients with esophageal cancer who underwent endoscopy (9 patients) and esophagectomy (405 patients) in Shanghai Chest Hospital in 2015 were reviewed, including 334 males and 80 females. Their tumor biological characteristics and short-term and long-term treatment results were analyzed.Results Patients in this group were predominantly aged 60 to 69 years (46.9%), and the tumor was mainly located in the middle thorax (50.7%). About 79.9% of the patients received trans-right thoracic esophagectomy, 44.4% received minimally invasive surgery; 388 (93.7%) patients accepted upfront esophagectomy without induction therapy, and 179 (43.2%) patients received postoperative adjuvant therapy. The R0 resection rate was 90.6%, and the 30- and 90-day mortality rates were 1.4% and 2.4%, respectively. The 4-year overall survival rate of the R0 resection patients was 65.7%.Conclusion Satisfactory long-term survival results can be obtained for thoracic esophageal cancer if R0 resection can be achieved by trans-right thoracic esophagectomy and extended lymphadenectomy combined with appropriate postoperative adjuvant treatment.

Citation： GUO Xufeng, JIANG Haoyao, HUA Rong, LI Bin, ZHANG Xiaobin, SUN Yifeng, LI Zhigang. Annual data report on surgical treatment of esophageal cancer in Shanghai Chest Hospital in 2015. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2020, 27(9): 1070-1074. doi: 10.7507/1007-4848.202001006 Copy

1.	Chen W, Zheng R, Baade PD, <italic>et al</italic>. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2.	Tachimori Y, Ozawa S, Numasaki H, <italic>et al</italic>. Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus, 2019, 16(3): 221-245.
3.	Amin MB, Edge S, Greene FL, et al. AJCC cancer staging manual. 8^th ed. New York: Springer, 2017. 185-202.
4.	中国抗癌协会食管癌专业委员会. 食管癌规范化诊治指南. 第 2 版. 北京: 中国协和医科大学出版社, 2013.
5.	Li B, Xiang J, Zhang Y, <italic>et al</italic>. Comparison of Ivor-Lewis vs. Sweet esophagectomy for esophageal squamous cell carcinoma: randomized clinical trial. JAMA Surg, 2015, 150(4): 292-298.
6.	Li B, Hu H, Zhang Y, <italic>et al</italic>. Extended right thoracic approach compared with limited left thoracic approach for patients with middle and lower esophageal squamous cell carcinoma: three-year survival of a prospective, randomized, open-label trial. Ann Surg, 2018, 267(5): 826-832.
7.	毛友生, 赫捷, 程贵余. 我国食管癌外科治疗的现状与未来对策. 中华肿瘤杂志, 2010, 32(6): 401-404.
8.	国家卫生健康委员会. 食管癌诊疗规范(2018 版). 中华消化病与影像杂志(电子版), 2019, 9(4): 158-192.
9.	Biere SS, van Berge Henegouwen MI, Maas KW, <italic>et al</italic>. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: multicentre, open-label, randomised controlled trial. Lancet, 2012, 379(9829): 1887-1892.
10.	Straatman J, van der Wielen N, Cuesta MA, <italic>et al</italic>. Minimally invasive versus open esophageal resection: three-year follow-up of thepreviously reported randomized controlled trial: the TIME trial. Ann Surg, 2017, 266(2): 232-236.
11.	Kataoka K, Takeuchi H, Mizusawa J, <italic>et al</italic>. A randomized phase Ⅲ trial of thoracoscopic versus open esophagectomy for thoracic esophageal cancer: Japan Clinical Oncology Group Study JCOG1409. Jpn J Clin Oncol, 2016, 46(2): 174-177.
12.	Yang Y, Zhang X, Li B, <italic>et al</italic>. Robot-assisted esophagectomy (RAE) versus conventional minimally invasive esophagectomy (MIE) for resectable esophageal squamous cell carcinoma: protocol for a multicenter prospective randomized controlled trial (RAMIE trial, robot-assisted minimally invasive esophagectomy). BMC Cancer, 2019, 19(1): 608-608.
13.	Ando N, Kato H, Igaki H, <italic>et al</italic>. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol, 2012, 19(1): 68-74.
14.	van Hagen P, Hulshof MC, van Lanschot JJ, <italic>et al</italic>. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012, 366(22): 2074-2084.
15.	Shapiro J, van Lanschot JJ, Hulshof MCCM, <italic>et al</italic>. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctionalcancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol, 2015, 16(9): 1090-1098.
16.	Hong Y, Hui L, Yuping C, <italic>et al</italic>. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial. J Clin Oncol, 2018, 36(27): 2796-2803.

1. Chen W, Zheng R, Baade PD, <italic>et al</italic>. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
2. Tachimori Y, Ozawa S, Numasaki H, <italic>et al</italic>. Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus, 2019, 16(3): 221-245.
3. Amin MB, Edge S, Greene FL, et al. AJCC cancer staging manual. 8^th ed. New York: Springer, 2017. 185-202.
4. 中国抗癌协会食管癌专业委员会. 食管癌规范化诊治指南. 第 2 版. 北京: 中国协和医科大学出版社, 2013.
5. Li B, Xiang J, Zhang Y, <italic>et al</italic>. Comparison of Ivor-Lewis vs. Sweet esophagectomy for esophageal squamous cell carcinoma: randomized clinical trial. JAMA Surg, 2015, 150(4): 292-298.
6. Li B, Hu H, Zhang Y, <italic>et al</italic>. Extended right thoracic approach compared with limited left thoracic approach for patients with middle and lower esophageal squamous cell carcinoma: three-year survival of a prospective, randomized, open-label trial. Ann Surg, 2018, 267(5): 826-832.
7. 毛友生, 赫捷, 程贵余. 我国食管癌外科治疗的现状与未来对策. 中华肿瘤杂志, 2010, 32(6): 401-404.
8. 国家卫生健康委员会. 食管癌诊疗规范(2018 版). 中华消化病与影像杂志(电子版), 2019, 9(4): 158-192.
9. Biere SS, van Berge Henegouwen MI, Maas KW, <italic>et al</italic>. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: multicentre, open-label, randomised controlled trial. Lancet, 2012, 379(9829): 1887-1892.
10. Straatman J, van der Wielen N, Cuesta MA, <italic>et al</italic>. Minimally invasive versus open esophageal resection: three-year follow-up of thepreviously reported randomized controlled trial: the TIME trial. Ann Surg, 2017, 266(2): 232-236.
11. Kataoka K, Takeuchi H, Mizusawa J, <italic>et al</italic>. A randomized phase Ⅲ trial of thoracoscopic versus open esophagectomy for thoracic esophageal cancer: Japan Clinical Oncology Group Study JCOG1409. Jpn J Clin Oncol, 2016, 46(2): 174-177.
12. Yang Y, Zhang X, Li B, <italic>et al</italic>. Robot-assisted esophagectomy (RAE) versus conventional minimally invasive esophagectomy (MIE) for resectable esophageal squamous cell carcinoma: protocol for a multicenter prospective randomized controlled trial (RAMIE trial, robot-assisted minimally invasive esophagectomy). BMC Cancer, 2019, 19(1): 608-608.
13. Ando N, Kato H, Igaki H, <italic>et al</italic>. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol, 2012, 19(1): 68-74.
14. van Hagen P, Hulshof MC, van Lanschot JJ, <italic>et al</italic>. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012, 366(22): 2074-2084.
15. Shapiro J, van Lanschot JJ, Hulshof MCCM, <italic>et al</italic>. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctionalcancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol, 2015, 16(9): 1090-1098.
16. Hong Y, Hui L, Yuping C, <italic>et al</italic>. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial. J Clin Oncol, 2018, 36(27): 2796-2803.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Annual data report on surgical treatment of esophageal cancer in Shanghai Chest Hospital in 2015

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content